A trial of emibetuzumab for non small cell lung cancer that had stopped responding to erlotinib (CHIME)

Cancer type:

Lung cancer
Non small cell lung cancer




Phase 2

This trial looked at emibetuzumab for non small cell lung cancer which had spread and got worse despite having erlotinib. It was for people who had change to a gene Open a glossary item called MET in their lung cancer cells.

It was open for people to join between 2013 and 2014. The team presented the results at a conference in 2016. There is a link to more information in the ‘Summary of results’ section below.

More about this trial

Erlotinib is a targeted treatment that doctors use to treat non small cell lung cancer (NSCLC). But sometimes it stops working and the cancer starts to grow again. 

Emibetuzumab (LY2875358) is a monoclonal antibody. It can seek out cancer cells by looking for specific proteins. Researchers wanted to find out if emibetuzumab can help people whose cancer has stopped responding to erlotinib.

The people taking part were put into 1 of 2 treatment groups at random:

  • half had emibetuzumab and erlotinib
  • half had emibetuzumab alone

The main aim of this trial was to find out if emibetuzumab, with or without erlotinib, is useful for non small cell lung cancer. This was for people who’d already had erlotinib but their cancer had started to grow again.

Summary of results

We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.

There is more information about the results in the links below.

Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC 
D. Ross Camidge and others
Presented at ASCO conference, abstract 9070.
Journal of Clinical Oncology, 2016. Volume 34, Number 15.

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants (Chime)
National Library of Medicine website.
Accessed March 2024.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Denis Talbot

Supported by

Eli Lilly and Company Limited
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 11118

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think